Social Media Ideas for Apogee Therapeutics

Apogee Therapeutics: Targeting Atopic Dermatitis

Apogee Therapeutics, Inc. (APGE) Discusses Positive Part B Results From Phase 2 APEX Trial of Zumilokibart in Atopic Der...

AbbVie to Acquire Apogee Therapeutics for $10.9B

Apogee’s lead candidate zumilokibart, an IL-13 inhibitor also called APG777, is a long-acting treatment that, according to the company, holds “pipeline-in-a-product potential” beca...

Why is Apogee Therapeutics stock surging today?

Apogee bags $1.3B Blackstone royalty funding deal to push eczema challenger into phase 3

Apogee Therapeutics has secured a promise of up to $1.3 billion in financing from Blackstone Life Sciences as the biotech gears up to take its anti-IL-13 antibody into phase 3.

AbbVie’s $11B Apogee Acquisition Brings an Eczema Drug With an Edge

Apogee Therapeutics brings AbbVie a long-acting antibody ready for Phase 3 testing in atopic dermatitis, also called eczema. This therapy’s pipeline in a product potential includes...

Apogee eczema drugs gets Blackstone backing, heads to Phase 3

The company made the announcement after a new round of research results bolstered the case for the experimental medicine, which may ultimately compete against Dupixent and Ebglyss.

Apogee Therapeutics Announces $1.3 Billion Strategic Financing Collaboration with Blackstone Life Sciences to Advance Ph...

Up to $1.3 billion in flexible, non-dilutive capital, including up to $800 million of synthetic royalty and access of up to $500 million in senior corporate debt - - Combined...

<![CDATA[AbbVie to Acquire Apogee Therapeutics in $10 Billion Deal]]>

AbbVie inks $10.9B Apogee buyout to bag hotly tipped eczema prospect

AbbVie has struck a deal to buy Apogee Therapeutics for $10.9 billion. The deal will give AbbVie control of a late-phase eczema drug candidate that could pose a threat to Eli Lilly...

Apogee’s Royalty Deal With Blackstone Will Fund Pivotal Test in Eczema and More

Blackstone Life Sciences is providing Apogee Therapeutics with up to $1.3 billion in non-dilutive financing, which the biotech will apply to a key test of its lead drug candidate i...

<![CDATA[Pharmaceutical Executive Daily: AbbVie Acquires Apogee Therapeutics for $10.9 Billion]]>

Apogee Enterprises, Inc. 2027 Q1 - Results - Earnings Call Presentation

AbbVie to acquire Apogee, staking nearly $11B on long-acting autoimmune drugs

AbbVie’s largest deal in more than half a decade adds a group of immune disease medications — among them a Dupixent competitor — the company believes to have “mega-blockbuster” sal...

Apellis Acquisition

Apellis Acquisition Anonymous (not verified) Sat, 07/11/2026 - 09:12 field_thread_url https://cafepharma.com/boards/threads/apellis-acquisition.715869/...

Apellis Acquisition

Apellis Acquisition Anonymous (not verified) Mon, 06/22/2026 - 00:00 field_thread_url https://cafepharma.com/boards/threads/apellis-acquisition.715869/...

Fresh off buyout, Akero execs reunite to advance long-acting psoriasis pill

Set to go public via a reverse merger, Avere has licensed from a prolific Chinese drugmaker rights to a potential threat to medicines like Skyrizi and Icotyde. 

Glaucoma Drug Fails Trial, But Bausch + Lomb Sees Opportunity in Another Eye Disease

A Bausch + Lomb drug from a 2025 acquisition missed primary and secondary goals of a Phase 2 test in glaucoma. Bausch now plans to develop this drug for geographic atrophy, aiming...

Precigen (PGEN) Secures FDA Orphan Drug Exclusivity for PAPZIMEOS

Attovia files for IPO to take on Sanofi and Regeneron’s Dupixent

Attovia Therapeutics has filed for an IPO to secure funding for assets, including a potential challenger to Sanofi and Regeneron’s Dupixent and Galderma’s Nemluvio.

Cash-strapped Alopexx reignites plans to go public via $30M IPO to fund infectious disease programs

Alopexx has resuscitated its plans for a public listing as the biotech seeks urgently needed funds to advance a pipeline that includes an infectious disease antibody that was once...

Ethyreal starts up with $101M and takes aim at a pair of immune diseases

The startup is developing a medicine that works differently than available treatments for thyroid eye disease and could benefit people with a related condition, too.

Parabilis Medicines’ Quest to Drug the Undruggable Picks Up $745M From Upsized IPO

Parabilis Medicines is developing a new type of peptide drug capable of hitting elusive disease targets inside cells. Cancer is the biotech’s initial focus, and the IPO cash will s...

Biogen ends Apellis research programs, cuts ‘small number’ of roles after $5.6B buyout

Biogen isn’t wasting any time integrating its multibillion-dollar purchase of Apellis, revealing plans to part ways with some of the biotech’s staffers and halt work on most of its...